Q1 2026 M&A deal flow preview: mid-market is hot, solo practices aren't.

Q1 2026 M&A deal flow preview: mid-market is hot, solo practices aren't.

Dental M&A pipeline for Q1 2026 shows consolidation appetite concentrated on three-to-five location DSOs and regional practice groups. Solo practices are being passed over unless they're in a major metro or they're doing $1M-plus in production.

Why? Scaling inefficiency. A PE firm that buys ten $400K practices spends the same integration effort as one $4M practice. The $4M practice already has operational sophistication and systems. The ten $400K practices are ten different PMSs, ten different billing approaches, and ten different cultures.

The solo operators getting deals are the ones who've already optimized. They've installed the systems a PE firm would install anyway. They've lifted case acceptance and collections. They're closer to 35% EBITDA because they've done the work. Those practices are trading 4.0x to 4.5x revenue (or 11-13x EBITDA). The unoptimized ones? 3.2x to 3.6x revenue.

Here's the positioning for Q2 and Q3: if you want to exit, the next 90 days are your labor window. Tighten scheduling. Reduce supplier costs. Run collections harder. Every point of EBITDA you add directly multiplies your exit price by 2.5x.

The practices that wait until mid-2026 to start optimizing will be competing against buyers who see standardized EBITDA by then. Get ahead now or discount later. That's the choice.